|Bid||0.3400 x 1582700|
|Ask||0.3550 x 3535900|
|Day's range||0.3370 - 0.3450|
|52-week range||0.2800 - 0.4800|
|Beta (5Y monthly)||0.61|
|PE ratio (TTM)||N/A|
|Earnings date||23 Feb 2023 - 27 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
The underwhelming share price performance of Cynata Therapeutics Limited ( ASX:CYP ) in the past three years would have...
Cynata Therapeutics Limited (ASX: "CYP" or "Cynata"), a clinical-stage biotechnology company specialising in cell therapeutics, is delighted to announce that the LUMC is funding an important clinical trial to investigate Cynata's Cymerus™ MSCs as a treatment for renal graft rejection and to potentially reduce the requirement for anti-rejection drugs.